Amylyx Pharmaceuticals Financial Statements (AMLX)
|
|
|
|
Report date
|
|
|
09.11.2023 |
22.02.2024 |
09.05.2024 |
08.08.2024 |
07.11.2024 |
|
07.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
102.7 |
108.4 |
88.6 |
1.02 |
0.416 |
|
198.5 |
|
Operating Income, bln rub |
|
|
18.7 |
1.93 |
-122.1 |
-53.4 |
-75.7 |
|
-249.3 |
|
EBITDA, bln rub |
? |
|
19.0 |
2.24 |
-121.8 |
-53.2 |
-39.2 |
|
-212.0 |
|
Net profit, bln rub |
? |
|
20.9 |
4.73 |
-118.8 |
-72.7 |
-72.7 |
|
-259.5 |
|
|
OCF, bln rub |
? |
|
-5.17 |
13.6 |
-0.489 |
-66.6 |
-41.6 |
|
-95.1 |
|
CAPEX, bln rub |
? |
|
0.357 |
0.356 |
0.067 |
0.089 |
0.019 |
|
0.531 |
|
FCF, bln rub |
? |
|
-5.53 |
13.2 |
-0.556 |
-66.7 |
-41.6 |
|
-95.6 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
|
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
78.8 |
97.2 |
94.1 |
44.8 |
75.3 |
|
311.3 |
|
Cost of production, bln rub |
|
|
5.22 |
9.36 |
116.7 |
7.63 |
0.809 |
|
134.5 |
|
R&D, bln rub |
|
|
30.0 |
44.9 |
36.3 |
23.1 |
21.2 |
|
125.6 |
|
Interest expenses, bln rub |
|
|
0.000 |
3.46 |
0.000 |
0.000 |
0.000 |
|
3.46 |
|
|
Assets, bln rub |
|
|
466.6 |
517.5 |
417.5 |
332.2 |
250.7 |
|
250.7 |
|
Net Assets, bln rub |
? |
|
418.4 |
433.4 |
324.4 |
261.3 |
196.2 |
|
196.2 |
|
Debt, bln rub |
|
|
4.77 |
4.24 |
3.69 |
3.14 |
2.57 |
|
2.57 |
|
Cash, bln rub |
|
|
355.0 |
371.4 |
373.3 |
309.8 |
234.4 |
|
234.4 |
|
Net debt, bln rub |
|
|
-350.3 |
-367.1 |
-369.6 |
-306.7 |
-231.8 |
|
-231.8 |
|
|
Ordinary share price, rub |
|
|
18.3 |
14.7 |
2.84 |
1.90 |
3.24 |
|
|
|
Number of ordinary shares, mln |
|
|
67.4 |
67.4 |
67.9 |
68.0 |
68.1 |
|
68.1 |
|
|
Market cap, bln rub |
|
|
1 234 |
992 |
193 |
129 |
221 |
|
0 |
|
EV, bln rub |
? |
|
884 |
625 |
-177 |
-177 |
-11 |
|
-232 |
|
Book value, bln rub |
|
|
418 |
433 |
324 |
261 |
196 |
|
196 |
|
|
EPS, rub |
? |
|
0.31 |
0.07 |
-1.75 |
-1.07 |
-1.07 |
|
-3.81 |
|
FCF/share, rub |
|
|
-0.08 |
0.20 |
-0.01 |
-0.98 |
-0.61 |
|
-1.40 |
|
BV/share, rub |
|
|
6.21 |
6.43 |
4.78 |
3.84 |
2.88 |
|
2.88 |
|
|
EBITDA margin, % |
? |
|
18.5% |
2.06% |
-137.4% |
-5 203% |
-9 432% |
|
-106.8% |
|
Net margin, % |
? |
|
20.3% |
4.36% |
-134.0% |
-7 107% |
-17 477% |
|
-130.7% |
|
FCF yield, % |
? |
|
-4.28% |
1.08% |
8.01% |
-46.1% |
-43.3% |
|
|
|
ROE, % |
? |
|
0.44% |
11.4% |
-21.9% |
-63.5% |
-132.2% |
|
-132.2% |
|
ROA, % |
? |
|
0.39% |
9.52% |
-17.0% |
-49.9% |
-103.5% |
|
-103.5% |
|
|
P/E |
? |
|
672.3 |
20.1 |
-2.71 |
-0.78 |
-0.85 |
|
0 |
|
P/FCF |
|
|
-23.4 |
92.9 |
12.5 |
-2.17 |
-2.31 |
|
0 |
|
P/S |
? |
|
4.20 |
2.61 |
0.48 |
0.43 |
1.12 |
|
0 |
|
P/BV |
? |
|
2.95 |
2.29 |
0.59 |
0.49 |
1.12 |
|
0 |
|
EV/EBITDA |
? |
|
-123.8 |
15.8 |
2.21 |
1.15 |
0.05 |
|
1.09 |
|
Debt/EBITDA |
|
|
49.0 |
-9.25 |
4.62 |
1.99 |
1.09 |
|
1.09 |
|
|
R&D/CAPEX, % |
|
|
8 414% |
12 616% |
54 169% |
25 999% |
111 774% |
|
23 650% |
|
|
CAPEX/Revenue, % |
|
|
0.35% |
0.33% |
0.08% |
8.70% |
4.57% |
|
0.27% |
|
| Amylyx Pharmaceuticals shareholders |
